Lexaria Bioscience's book value per share for the quarter that ended in Feb. 2024 was $0.53.
During the past 12 months, Lexaria Bioscience's average Book Value Per Share Growth Rate was -37.10% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -23.50% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -6.80% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -7.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Lexaria Bioscience was 79.80% per year. The lowest was -66.10% per year. And the median was -14.10% per year.
During the past 13 years, the highest P/B Ratio of Lexaria Bioscience was 64.87. The lowest was 0.32. And the median was 6.61.
Lexaria Bioscience Book Value per Share Historical Data
The historical data trend for Lexaria Bioscience's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Lexaria Bioscience's Book Value per Share
For the Biotechnology subindustry, Lexaria Bioscience's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lexaria Bioscience's PB Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lexaria Bioscience's PB Ratio distribution charts can be found below:
* The bar in red indicates where Lexaria Bioscience's PB Ratio falls into.
Lexaria Bioscience Book Value per Share Calculation
Lexaria Bioscience's Book Value Per Share for the fiscal year that ended in Aug. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.
Lexaria Bioscience (NAS:LEXX) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Lexaria Bioscience Book Value per Share Related Terms
Thank you for viewing the detailed overview of Lexaria Bioscience's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Lexaria Bioscience (Lexaria Bioscience) Business Description
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH has the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. The Company has four reportable segments: Intellectual Property Licensing, B2B Production, Research and Development and Corporate. It earns maximum revenue from Intellectual Property Licensing.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LEXX has been successfully added to your 